DrugDashboards

Clotrimazole Topical Solution USP, 1%

Clotrimazole Topical Solution USP, 1% · CLOTRIMAZOLE 10 mg/mL · Solution · Topical · ScieGen Pharmaceuticals, Inc

NDC 50228-0502-30 · 1 BOTTLE in 1 CARTON / 30 mL in 1 BOTTLE · ANDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 17% over the past year, to $0.4425 per mL. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.4425per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicaid generic ceiling (FUL)$0.4425per MLweighted avg manufacturer price $0.2259 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 52817-0800-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.6910per unit
middle half $0.5511$1.16 · 5,097 plans · Apr 1, 2026
Est. net of rebates
≈ $0.6910
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
93%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 52%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$0.2$0.4$0.6Nov 2025Sep 2026$0.4425
11 price points · per ML · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$42.35
Reported to Texas DSHS · 2026 annual filing · Sciegen

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$4,372
203 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

5Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 5 active manufacturers+5

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for clotrimazole (other) in the next 90 days

sole-source market · 2 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA216569
TE code
AT
Approval date
Oct 16, 2023
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Clotrimazole Topical Solution USP, 1% (Solution)

LabelerStrengthFirst seenLast seen
Akron Pharma Inc.CLOTRIMAZOLE 10 mg/mLJul 15, 2026Sep 2, 2026
Allegis Holdings, LLCCLOTRIMAZOLE 10 mg/mLJul 15, 2026Sep 2, 2026
Bryant Ranch PrepackCLOTRIMAZOLE 10 mg/mLJul 15, 2026Sep 2, 2026
ScieGen Pharmaceuticals, IncCLOTRIMAZOLE 10 mg/mLJul 15, 2026Sep 2, 2026
TruPharma LLCCLOTRIMAZOLE 10 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Clotrimazole Topical Solution USP, 1% — NDC 50228-0502-30," retrieved September 3, 2026, https://drugdashboards.com/drug/50228050230.

Free to cite with attribution — see how the data is put together.